{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:33:46Z","timestamp":1781890426398,"version":"3.54.5"},"reference-count":6,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,2]]},"DOI":"10.2478\/jtim-2023-0097","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T15:52:02Z","timestamp":1693669922000},"page":"309-311","source":"Crossref","is-referenced-by-count":3,"title":["A first case report of using chimeric antigen receptor T-cell immunotherapy to treat high-risk smoldering multiple myeloma"],"prefix":"10.2478","volume":"11","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbing","family":"Duan","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University , Beijing 100044 , China"},{"name":"Innovative Center of Hematology, Soochow University , Suzhou 215021, Jiangsu Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"key":"2023090412302561966_j_jtim-2023-0097_ref_001","doi-asserted-by":"crossref","unstructured":"Joseph NS, Dhodapkar MV, Lonial S. The Role of Early Intervention in High-Risk Smoldering Myeloma. Am Soc Clin Oncol Educ Book 2020;40:1\u20139.","DOI":"10.1200\/EDBK_278915"},{"key":"2023090412302561966_j_jtim-2023-0097_ref_002","doi-asserted-by":"crossref","unstructured":"Dhakal B, Hari PN, Usmani SZ, Hamadani M. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. Bone Marrow Transplant 2021;56:9\u201319.","DOI":"10.1038\/s41409-020-01023-w"},{"key":"2023090412302561966_j_jtim-2023-0097_ref_003","doi-asserted-by":"crossref","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 2020;13:125.","DOI":"10.1186\/s13045-020-00962-7"},{"key":"2023090412302561966_j_jtim-2023-0097_ref_004","doi-asserted-by":"crossref","unstructured":"Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncol 2015;1:746\u201354.","DOI":"10.1001\/jamaoncol.2015.2010"},{"key":"2023090412302561966_j_jtim-2023-0097_ref_005","doi-asserted-by":"crossref","unstructured":"Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 2019;6:e521\u20139.","DOI":"10.1016\/S2352-3026(19)30115-2"},{"key":"2023090412302561966_j_jtim-2023-0097_ref_006","doi-asserted-by":"crossref","unstructured":"Shi J, Ni Y, Li J, Qiu H, Miao K. Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review. Oncol Lett 2015;9:2208\u201310.","DOI":"10.3892\/ol.2015.3043"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/jtim-2023-0097\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/jtim-2023-0097\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T12:32:36Z","timestamp":1693830756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.2478\/jtim-2023-0097\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":6,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,2]]},"published-print":{"date-parts":[[2023,9,2]]}},"alternative-id":["10.2478\/jtim-2023-0097"],"URL":"https:\/\/doi.org\/10.2478\/jtim-2023-0097","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}